RIS Rx has introduced a refreshed brand identity and messaging platform that underscores its growing role in tackling one of the pharmaceutical industry’s most complex financial and operational issues—Gross-to-Net (GTN) revenue leakage.
The rebranding highlights a specialized discipline the company has been instrumental in developing: real-time GTN Revenue Protection. This approach is designed to proactively detect and prevent revenue leakage before it impacts pharmaceutical manufacturers’ bottom lines.
Within the pharmaceutical sector, the Gross-to-Net spread remains one of the most significant yet opaque elements of financial reporting. Factors such as pharmacy benefit manager (PBM) policies—including maximizers and accumulators—payer guidelines, pharmacy-level transactions, and patient eligibility requirements often create gaps in visibility. These gaps can result in substantial portions of funds, originally intended to improve patient affordability, being misallocated or lost.
RIS Rx addresses this challenge through a platform that integrates seamlessly with existing affordability and patient support infrastructures. By enabling real-time monitoring, intervention, and analytics prior to a patient’s first prescription fill, the platform ensures more precise allocation of financial assistance. Through advanced patient segmentation and program verification, manufacturers can direct resources to the right patients at the right time.
Also Read: MediStreams Unveils End-to-End Payment Reconciliation Platform for Healthcare Finance
“Pharmaceutical manufacturers are increasingly realizing that GTN is not just an accounting exercise—it’s an operational challenge that directly impacts patient access and brand performance,” said Gerard Rivera, CEO and Co-founder of RIS Rx. “Our mission is to bring integrity, visibility, and accountability to that process so manufacturers can ensure the support they allocate for patients actually reaches those patients.”
Established by pharmacists, RIS Rx combines clinical knowledge with data-driven insights to detect, mitigate, and measure GTN leakage across various affordability programs. Its solutions are designed for seamless integration with existing copay vendors and hub service providers, allowing for rapid implementation without disrupting patient experiences or operational workflows.
The company reports that its solutions have already enabled pharmaceutical manufacturers to achieve over $1 billion in annual savings across multiple brands and programs.
“Gross-to-Net has historically been managed through retrospective analysis and periodic audits,” said Stephen Hom, Co-founder, EVP and Chief Operating Officer of RIS Rx. “GTN Revenue Protection introduces a proactive model—one that enables manufacturers to identify and prevent leakage in real time, before those dollars are lost.”
By delivering continuous reporting, compliance assurance, and real-time visibility into program performance, RIS Rx empowers pharmaceutical companies to maximize the effectiveness of their patient support investments while maintaining strict financial oversight.
